[ Return to Index ]

CalbaTech advisory member contributes stem cell intellectual property, ranging from banking of stem cells to regeneration of tissues

CalbaTech, Inc. (Irvine, CA), an emerging life sciences company concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, said that Dr. Jason Van Tassel has provided three pieces of stem cell related intellectual property to CalbaTech's wholly owned subsidiary LifeStem, Inc. Earlier this week, LifeStem announced that it is finalizing plans to offer a stem cell collection and storage service in selected markets.

"We're pleased to have the support and contribution of Dr. Van Tassel," said CalbaTech CEO James DeOlden. "All three pieces of intellectual property complement our efforts in the stem cell arena and we're focused on developing them through our stem cell subsidiary LifeStem," Mr. DeOlden added.

The three pieces of intellectual property contributed by Dr. Van Tassel are related to therapeutic uses of autologous adult stem cells, and range from intellectual property related to the banking of stem cells to regeneration of tissue through the use of stem cells. The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent and Trademark Office.

Dr. Van Tassel previously developed a novel method of injecting stem cells into diseased tissue through the use of a modified endoscope for which the company has filed for patent protection.

CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. It is concentrating on acquiring, incubating and developing early stage life science based companies that are developing next generation products and technologies, both in the United States and in the United Kingdom. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute breakthrough innovation in areas of biological discovery.

LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The company has filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service.

CalbaTech, Inc.
+1-949-707-5365
www.CalbaTech.com